Trial Profile

A prospective, open label, multicenter, efficacy and safety study of several infusions of Promethera HepaStem in Urea Cycle Disorders pediatric patients

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 25 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mesenchymal stem cell therapy (Primary)
Indications Argininosuccinic aciduria; Inborn urea cycle disorders
Focus Therapeutic Use
Sponsors Promethera Biosciences

Most Recent Events

22 Jul 2022 Status changed from recruiting to completed.
05 Oct 2021 This trial has been completed in Poland, according to European Clinical Trials Database record. (2019-08-01)
23 Jan 2021 This trial has been completed in Belgium and France, according to European Clinical Trials Database record. (Global end date:2019-08-01)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com